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chotics. During the ﬁrst 150 days from the initiation 
of therapy, rivastigmine patients were 81% (RR = 0.19;
95% CI: 0.05–0.63) less likely to use antipsychotic drugs
compared to non-ChEI users. CONCLUSIONS: AD
patients who take rivastigmine are less likely to take
antipsychotics compared to those not taking ChEIs. These
ﬁndings imply that rivastigmine use may delay the 
progression of the development of behavioral symptoms
of AD.
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USE OF WHO’S ICIDH-2 CLASSIFICATION
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Chisolm D1, Pathak DS1,Weis KA2
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OBJECTIVES: This study explores the use of the WHO’s
ICIDH-2 in determining domains of mental functioning
impairment in migraineurs. METHODS: Seventy-one
migraine functioning questions were generated from
focus groups in the US and Germany and classiﬁed using
the ICIDH-2 system. A Phase I questionnaire imple-
mented in the US and Germany was used to identify items
of greatest relevance to migraineurs. Principal compo-
nents analysis (PCA) with Varimax rotation was used to
identify factors from relevant items in Phase I data. These
items were tested in a Phase II study in the US and
Germany and conﬁrmatory factor analysis (CFA) was
conducted to determine if the factor structure found in
Phase I remained intact. Statistics to assess ﬁt of the CFA
model included the chi-squared test which is insigniﬁcant
in good ﬁtting models, the RMSEA in which values less
than 0.05 indicate good ﬁt, and the NNFI which should
be at least 0.95 to indicate a strong model. RESULTS:
The Phase I PCA conducted in the US sample identi-
ﬁed four factors consistent with the ICIDH-2:
“Energy/Sleep”, “Perception”, “Attention/Thought”, and
“Emotion”. In Germany, the same factors were identiﬁed
with the exception of “Energy/Sleep”. Emotion items
were not included in Phase II in order to focus on func-
tioning alone. CFA of the Phase II data found that a
model including “Attention/Thought”, “Perception”, and
“Energy/Sleep” did not ﬁt well. After additional item
reduction, however, a model with “Perception” and
“Attention/Thought” showed excellent performance in
CFA with a chi-squared value of 33.04 (d.f. = 26, p =
0.16), RMSEA of 0.042 (90%CI 0.00–0.08) and NNFI
of 0.99. CONCLUSIONS: The ICIDH-2 mental func-
tioning dimensions with the greatest impact on
Migraineurs are Perception and Attention/Thought. Emo-
tional function was also an important factor. This
research supports the hypothesis that the ICIDH-2 can be
used in classifying areas of impairment for outcomes
assessment.
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OBJECTIVES: Attention deﬁcit hyperactivity disorder
(ADHD) is a prevalent mental health condition, occur-
ring in 3–5% of children. Although stimulant medications
are a recommended treatment for this disorder, physi-
cians’ views of these medications have not been system-
atically evaluated. This study examined physician
perceptions of using medications to treat ADHD symp-
toms in children and/or adolescents. METHODS: A
survey was developed with four physician experts in treat-
ing ADHD in children. The survey was pilot tested with
a sample of 10 practicing physicians. A sample of 1000
physicians, with a history of prescribing stimulant med-
ications to children and/or adolescents, was randomly
selected and mailed a 30-item survey. Items were rated on
a 7-point response scale (strongly agree, agree, slightly
agree, undecided, slightly disagree, disagree, strongly dis-
agree). RESULTS: A total of 365 physicians responded to
the survey, for a 36.5% response rate. Over 98% physi-
cians agreed that ADHD symptoms cause problems in
pediatric patients and that stimulants are effective in
treating ADHD. The stimulant side effects 
of decreased appetite/weight loss, sleep disruption, and
exacerbation of anxiety were a concern to 88%, 74%,
and 63% of physicians, respectively. Physicians reported
that controlled medications for children and/or adoles-
cents with ADHD are a burden for themselves (55%
agreed), for their staff (61% agreed), and for parents
(66% agreed). Diversion of ADHD medication was a
concern to 53% of respondents. Approximately 55% of
physicians responded that they would prefer prescribing
a non-stimulant medication with a FDA-indication for
treating children and/or adolescents instead of a stimu-
lant medication. CONCLUSIONS: Although physicians
overwhelmingly perceive stimulant medications as being
effective for treating ADHD symptoms in children and/or
adolescents, the majority would prefer a non-stimulant
medication. Their concerns related to side effects, diver-
sion, and burden of prescribing associated with stimu-
lants may be reasons for their preference.
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OBJECTIVES: Traditional database methodology suggest
patient selection be done through ICD codes when inter-
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ested in a speciﬁc disease and through NDC codes when
interested in the medication. However, this methodology
may be different for a population of pain patients, as 
no ICD code speciﬁc for pain exists. The purpose of this
study was to understand the differences in data pulled
using NDC versus ICD-9 codes to identify a pain popu-
lation. METHODS: United Healthcare pharmacy and
medical claims from continuously enrolled individuals in
1998 were used for examination. In one method patients
were selected if they were at least 18 years of age as of
January 1, 1998, were continuously enrolled with a drug
and medical beneﬁt and had at least one medical claim
with a pain-related diagnosis (cancer, ﬁbromyalgia, low
back pain, neuropathic pain, and osteoarthritis) in 1998.
The other method differed by selecting patients who had
at least one pharmacy claim with an NDC for pain med-
ication (long acting opioid, short acting opioid, combi-
nation opioid and NSAID). RESULTS: Using the ICD
code method, 233,390 patients were selected. Low back
pain had the highest amount of people, constituting 40%,
while neuropathic pain had the least, 5%. The average
age of patients with pain-related diagnosis was 46.6.
Using the pharmacy claims method, 274,830 were
selected. The most commonly prescribed pain medication
was combination opioids (36%), and the least was long
acting opioids (0.7%). The mean age for this population
was 43.2. The overlap in patient selection was 84.9%
with the prescription drug population being a larger
cohort. CONCLUSIONS: Using NDC codes to select
users of pain medications in a database revealed more
users than those selected through ICD codes speciﬁc for
conditions where pain exists. However, an 85% overlap
in patient selection suggests that the diseases selected
capture a majority of pain-related conditions.
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OBJECTIVES: To deﬁne factors inﬂuencing the uptake
and use of newer, disease-altering agents such as
Betaseron, Avonex, Rebif and Copaxone in treatment of
multiple sclerosis (MS). METHODS: The analytic ﬁle for
the study was derived from claims and eligibility data for
a privately insured population for 1996–2000. Patients
were followed for a minimum of one year, starting with
their ﬁrst conﬁrmed diagnosis of MS. Disease Staging
software was used to establish disease type (e.g., relaps-
ing/remitting) during the study period. Disease type, cor-
morbidities, demographics, and insurance information
were measured to assess their importance on the odds of
receiving a disease-altering agent. A Cox proportional
hazard analysis was used to estimate the effect of each
variable. RESULTS: Forty-one percent of the 1807 MS
patients eventually were ever treated with the newer
disease-altering drugs. Of note is the elapsed time of
average of 305.2 days between the conﬁrmed ﬁrst-
observed MS diagnosis and ﬁrst prescription for one of
the newer agents. The hazard analyses found that older
patients, early retirees, and patients with union afﬁlia-
tion received the newer drugs less often. Gender, type of
private insurance, and location (urban versus rural) did
not inﬂuence the odds of getting the drugs. Patients resid-
ing in the Southern and Western United States, those that
entered the study in later years (1997–1999), and patients
with lower medication co-payments received the medica-
tions more often. Patients with a history of either depres-
sion or heart disease (relative contra-indications to these
drugs) received them less often. The variables designed to
measure disease severity suggested that stable patients,
those neither too sick nor healthy, received the drugs
more often. CONCLUSIONS: The use disease modifying
drugs for the treatment of MS introduced in the 1990s is
observed in a lower percentage of patients, and with a
greater delay from the date of conﬁrmed diagnosis than
anticipated given clinical literature for these newer agents.
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OBJECTIVES: To describe Three-Times daily (TID)
methylphenidate (MPH) therapy in children with atten-
tion-deﬁcit/hyperactivity disorder (ADHD) and to
measure the extent of compliance with TID MPH
therapy. METHODS: Parents of children aged 6–12 years
with ADHD receiving either MPH or dextroamphetamine
were invited to participate in a survey via newspaper ads
placed in 2 major Canadian cities (Toronto and Mon-
treal). Eligibility criteria were: treatment with TID MPH
and treatment duration of at least one month. Purposes
of the study and eligibility criteria were not known to
callers. RESULTS: One hundred seventy seven callers
responded to the ads. Of these, 60 (34%) fulﬁlled eligi-
bility criteria. The mean age of children with ADHD was
8.8 years; 78% were boys. Mean daily dose was 34mg;
mean treatment duration was 28.6 months. Twenty
percent had taken a drug holiday in the past 2 weeks
(mean 1.8 days). Doses were taken at approximately 7:30
AM, noon, and 4PM. A parent was primarily responsi-
ble for administering the 1st and 3rd doses. School per-
sonnel or teachers tended to administer the 2nd dose.
Seventy three percent reported their child missed doses
from time to time. Fifty three percent reported missing
doses, excluding drug holidays, in the past 2 weeks (mean
